CONTINUING MEDICAL EDUCATION (CME) QUESTIONS|
March 20, 2025
Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL
CME
Blood (2025) 145 (12): 1334.
Connected Content
A related article has been published:
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
Citation
Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL. Blood 2025; 145 (12): 1334. doi: https://doi.org/10.1182/blood.2025028638
Download citation file: